Biotron Limited · ASX:BIT
Biotron — Australian Life Science Investment Summit 2011
10 slides from Biotron's conference presentation, Oct 19, 2011
Slide 1: Presentation to Investors (ASX cover letter)
Level 2, 66 Hunter Street Sydney NSW 2000 Tel: (61-2) 9300 3344 Fax: (61-2) 9221 6333 E-mail: pnightingale@biotron.com.au For personal use only Website: www.biotron.com.au 19 October 2011 The Manager Companies ASX Limited 20 Bridge Street Sydney NSW 2000 (10 pages by email) Dear Madam PRESENTATION T
Slide 2: Novel Small-Molecule Antiviral Drugs
For personal use only ASX:BIT Novel Small-Molecule Antiviral Drugs Australian Life Science Investment Summit October 2011 Michelle Miller, CEO +61 412 313329 mmiller@biotron.com.au
Slide 3: Forward Looking Statements
Forward Looking Statements For personal use only This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited and certain of the plans and objectives of its management. These statements are statemen
Slide 4: Biotron Limited Overview
Biotron Limited Overview For personal use only • Established in 1999, spin-out from Australian National University • ASX listing Jan 2001 (ASX:BIT) • Focus on developing novel antiviral drugs • Targeting specific class of proteins called Viroporins found in broad range of viruses • Key Targets: Hepa
Slide 5: Biotron's Pipeline
Biotron’s Pipeline For personal use only • Two clinical phase programs: – Hepatitis C virus and HIV Clinical Trials Project Target Discovery Preclinical Phase Ia Ph Ib Ph 2a Ph 2b Hep C p7 HIV Vpu Dengue M protein Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au
Slide 6: BIT225 and Hepatitis C
BIT225 and Hepatitis C For personal use only • New investigational oral drug for treating HCV infection • First in class; targets p7 protein – essential for virus assembly and release • Phase Ia (BIT225-001) – escalating single dose study (35 – 600 mg) in healthy male volunteers. Completed 2007 • Ph
Slide 7: Clinical Information
BIT225 Clinical Information For personal use only • Phase Ia - BIT225 well-tolerated at doses up to 600mg • Phase Ib - 200 mg BIT225 significantly reduced HCV levels compared to placebo (p=0.0002) • Phase 2a - BIT225 treatment resulted in ~1 log improvement in viral load reduction over and above IFN
Slide 8: BIT225 and HIV
BIT225 and HIV For personal use only • BIT225 is also a first-in-class new anti-HIV drug • New mode of action – targets Vpu • Targets HIV in viral reservoirs in vivo • Prevents production of infectious virus in reservoir cells • Potential to eliminate this long-lived source of virus in the body • Ph
Slide 9: Commercialization Strategy
BIT225 Commercialization Strategy For personal use only • HCV worldwide market ~US$2.8 billion; predicted to reach >US$10 billion • Over 170 million people infected • Documented need for new antiviral drugs; licensing space is very active • 18 Oct 2011 - Roche acquired Anadys (NASDAQ:ANDS), with Pha
Slide 10: Capital Structure
Capital Structure For personal use only Shares on issue 148 m Listed options ($0.10) 108 m (exp Dec 2011) Cash at 30 June 11 A$2.1 m Michelle Miller, CEO; +61 412 313329; mmiller@biotron.com.au Biotron Limited
Biotron — Australian Life Science Investment Summit 2011 on 6ix